POTS in Women: Why It's Different, Why Treatment Often Falls Short, and What Actually Helps

You've rearranged your life around it. You've learned to sit down where everyone else stands. You've learned that during the week before your period, you need to write off two or three days because the symptoms get worse. And you've probably tried the standard treatments: compression stockings, salt loading, and reconditioning. Some of it helped, but nothing fixed it.

Here's what doesn't get said often enough: the reason those treatments haven't been enough is not that you haven't tried hard enough, or because your case is unusually complicated. It's because standard treatments for postural orthostatic tachycardia syndrome (POTS) were never tested in women, even though 80–85% of patients with POTS are women.

Women don't just get POTS more than men. They get a more complex, more hormonally entangled version of it that shifts across their entire reproductive life—from the dizziness that started at puberty, through the pregnancies that make everything worse, to the perimenopause years when symptoms that had been manageable suddenly aren't.

Standard cardiovascular treatments—the medications, the compression, the salt—only manage the symptoms of a broken system. They don't fix the system. For women, whose POTS is rooted in autonomic nervous system dysregulation that shifts with every hormonal transition, that gap matters enormously.

This article covers:

1. Why Women Are So Much More Affected
2. Symptoms That Show Up Differently in Women
3. The Diagnosis Gap
4. The Hormonal Timeline
5. Why Standard Treatments Work Better for Men
6. Why a Neurological Approach Matters More for Women
7. Treating the Neurological Root Causes of POTS at Cognitive FX

If standard POTS treatments haven't given you the relief you need, our five-day neurologic-focused program may be a good next step. You can fill out a POTS intake form to get started, or call 385-446-4158 to speak with someone directly. 

Why Women Are So Much More Affected

Research shows that POTS has a distinct female predominance of approximately 80%, typically affecting women aged 15–45. The causes of POTS are varied—viral illness, pregnancy, trauma, autoimmune conditions, and connective tissue disorders like Ehlers-Danlos syndrome are among the most common triggers—but the biology behind why women are so disproportionately affected is still not fully understood.

What we do know is that women's cardiovascular physiology creates a more vulnerable baseline for orthostatic intolerance. After accounting for body size, women have lower blood volume, lower stroke volume, and less efficient venous return when upright. Their blood vessels also have greater vasodilatory capacity, meaning blood pools more readily in the lower body on standing. All of this makes the transition from lying down to standing harder to compensate for.

Beyond mechanics, hormones also play a significant role. We'll get into those in detail shortly.

Symptoms That Show Up Differently in Women

The core symptoms of POTS—increased heart rate when standing, lightheadedness, chest pain, shortness of breath, brain fog, fatigue, and exercise intolerance—affect both sexes. 

However, research comparing women and men with POTS consistently finds that women carry a significantly higher overall burden:

• More frequent lightheadedness, chest pain, and palpitations
• More gastrointestinal symptoms, including nausea, bloating, and constipation
• More neurological symptoms in the hands and feet
• Higher rates of co-occurring conditions: Ehlers-Danlos syndrome, mast cell activation syndrome (MCAS), autoimmune disorders including lupus and Sjögren's syndrome, endometriosis, ovarian cysts, and fibroids

Women with POTS are also more likely to have chronic fatigue syndrome (CFS) or overlap with CFS symptoms, which tends to produce more severe fatigue and exercise intolerance than either condition alone.

There are also symptoms that rarely appear in standard POTS resources. Women with POTS frequently experience reduced sexual desire and arousal, pelvic floor dysfunction, and chronic pelvic pain—all connected to the same autonomic root. In addition, research also links POTS to higher rates of interstitial cystitis and bladder pain syndrome in women.

The Diagnosis Gap—Why Women Wait Longer

Before being diagnosed with POTS, 69% of patients are wrongly diagnosed with an anxiety disorder. A further 59% are told their symptoms are "all in their head." This is despite the fact that POTS patients have no higher lifetime prevalence of psychiatric disorders than the general population. The symptoms are not psychological. 

The result:Women wait an average of five years for a POTS diagnosis compared to three years for men. Given that 80–85% of POTS patients are female, this gap affects the overwhelming majority of people with the condition.

The bias doesn't stop at diagnosis. Even after receiving a correct diagnosis, more women than men continue to be told their illness is psychological, and more are treated for a psychiatric disorder rather than for POTS itself.

Critically, this delay is not because women seek healthcare less often or describe their symptoms differently. Women and men approach the medical system at similar rates. The delay reflects clinician-dependent factors. In plain terms, there is a bias in how women's physical symptoms are interpreted.

What to do about it: Track your heart rate lying down and standing for several days before an appointment. Bring that data. Ask specifically for a tilt table test or active stand test—these are the standard tools used to diagnose POTS, and you are entitled to request them. About 34% of POTS patients have to suggest the diagnosis themselves, so it is worth coming prepared.

The Hormonal Timeline: POTS Across a Woman's Life

One of the things that makes POTS uniquely complicated for women is that hormones interact with the condition at every stage of reproductive life. Here's what that looks like from puberty through menopause.

Puberty: Where It Often Begins

POTS most commonly first surfaces in adolescents—particularly girls —and the timing is not coincidental. Research shows that pubertal hormones promote vasodilation and decrease blood volume, while progesterone suppresses some of the catecholamine—including norepinephrine—that help maintain blood pressure when standing. These combined effects can unmask an underlying vulnerability in the autonomic nervous system (ANS) that had previously gone undetected.

A teenager who starts fainting during sport, feeling dizzy after standing too quickly, or experiencing debilitating fatigue from her first period isn't necessarily going through "normal puberty." For parents and patients alike, these can be the first signs of POTS—and they're worth investigating rather than waiting out.

Monthly Cycle: A Recurring Trigger

Up to 80% of women with POTS experience symptom fluctuations tied to their menstrual cycle. The pattern is consistent: symptoms are worst during the premenstrual and early follicular phases, when both estrogen and progesterone are at their lowest, blood volume compensation is at its poorest, and the risk of presyncope is highest.

Symptoms tend to improve during the mid-luteal phase, when higher hormone levels drive greater activation of renal-adrenal hormones and more fluid retention, providing a natural buffer against orthostatic stress.

An important distinction: Hormonal fluctuations don't cause POTS. They affect how well the autonomic nervous system compensates for the orthostatic challenge. The system is the problem; hormones modulate how visible that problem becomes.

Practical tip: Tracking symptoms against the cycle phase gives both you and your provider meaningful data. Most POTS treatment plans don't account for this, but they should.

Pregnancy: Unpredictable Territory

No POTS medications have been approved as safe during pregnancy, which shapes the entire symptom management challenge from the outset. For women who already have the condition, this means navigating pregnancy with fewer tools. For women who develop POTS during pregnancy, it means being diagnosed into a treatment gap.

Pregnancy is a well-documented trigger for new-onset POTS, occurring in approximately 9% of cases. For women who already have the condition, symptoms during pregnancy are highly variable. Roughly 55% report improvement, while about 31% experience worsening.

Progesterone relaxes smooth muscle in blood vessel walls to support blood flow to the fetus, but in someone with POTS, this can further drop blood pressure and reduce cerebral circulation. Elevated estrogen simultaneously affects autonomic neurotransmitter activity in ways that can worsen symptoms. Diagnosis is frequently missed during pregnancy because dizziness, rapid heartbeat, and fatigue are commonly attributed to normal pregnancy changes.

Postpartum: Where Women Are Most Blindsided

After delivery, estrogen and progesterone drop sharply, destabilizing autonomic regulation at the exact moment a new mother needs to function at her best. Sleep deprivation compounds the instability further.

Approximately 30–50% of women with pre-existing POTS report worsening symptoms after delivery, and for a proportion of previously healthy women, pregnancy triggers entirely new-onset POTS. The dangerous overlap is that postpartum POTS symptoms—dizziness, rapid heartbeat, fatigue, brain fog—are routinely mistaken for postpartum depression or normal new-mother exhaustion. If your symptoms feel physical and are consistently worse when you stand up, they deserve proper evaluation.

Perimenopause and Menopause: The Overlooked Stage

Menopausal symptoms can begin 7–10 years before menopause, meaning many women in their late 30s and 40s experience worsening POTS or develop it for the first time without anyone connecting the dots.

Part of the reason is overlap: Both perimenopause and POTS produce heat intolerance, irregular heart rate, sleep disruption, and lightheadedness. It's easy for clinicians to attribute everything to the menopause transition. 

Clinically, three patterns emerge: 

1. Symptoms worsen during perimenopause as hormonal volatility increases autonomic load
2. Symptoms improve as hormones stabilize post-menopause
3. Or POTS appears for the first time at this life stage

One relevant finding: Clinical observation and research both suggest that orthostatic tolerance is actually highest in postmenopausal women, and many women find that their symptoms lessen or resolve after the menopausal transition completes. This doesn't help during the perimenopause years themselves—which can last a decade—but it does suggest the condition isn't necessarily a permanent trajectory.

Why Standard Treatments Work Better for Men

The standard POTS treatment framework was largely built for men, then applied most heavily to the population it was least designed for. Here is what the evidence shows when you look at the most common treatments through a sex-specific lens.

Medication

Beta blockers are prescribed to women with POTS more often than men, partly because more women are diagnosed by a cardiologist. Other commonly used medications include fludrocortisone to expand blood volume, midodrine to constrict blood vessels and improve venous return, and pyridostigmine to reduce orthostatic tachycardia by enhancing parasympathetic tone. Each targets a different aspect of the cardiovascular picture.

But the data on how women respond to these medications, particularly beta blockers, is increasingly difficult to ignore. In POTS-specific research, young girls treated with metoprolol had a 503% increased risk of poor prognosis compared to males.

Broader cardiovascular research points in the same direction. A major 2025 clinical trial (REBOOT) that studied beta blockers after myocardial infarction (not POTS specifically) found that women treated with beta blockers had a 45% higher relative risk of serious outcomes compared to women not on them, while men showed no such excess risk. Researchers concluded that "a one-size-fits-all approach may not be appropriate" for beta blocker prescribing by sex. The clinical population is different, but the convergence of findings across contexts strengthens the concern: beta blockers may not carry the same risk-benefit profile for women as they do for men.

Exercise

Exercise training is the most evidence-supported non-pharmacological treatment for POTS, and it outperforms beta blockers on the outcomes that matter most. Research directly comparing the two found that exercise, not medication, improved overall patient wellbeing, quality of life, and hemodynamic responses during prolonged standing. This benefit was demonstrated in a study cohort that was almost entirely female.

The challenge for women is sustaining it. Symptoms worsen cyclically around menstruation, creating a recurring window where exercise tolerance is lowest. Women who developed POTS postpartum are managing an infant while debilitated. And women who waited years for a diagnosis—the majority, given the five-year average—arrive at treatment more deconditioned than their male counterparts who tend to receive faster diagnoses and more commonly have a specific-event onset.

Salt Intake, Fluids, and Compression

Increased salt and fluid intake and compression garments work by expanding low blood volume and reducing the amount of blood that pools in the lower body. These are among the most consistently recommended treatments.

The sex-specific limitation for women is consistency. During the mid-luteal phase of the menstrual cycle, hormones naturally drive better fluid retention and improved standing tolerance. When estrogen and progesterone drop in the premenstrual and early follicular phases, that hormonal buffer disappears. No amount of salt intake or compression garments can replicate it, which is why women often find these strategies work better at certain points in their cycle than others. The relief they provide can also feel frustratingly inconsistent in a way that men typically don't report.

The Bottom Line

Women with POTS carry a higher symptom burden, more comorbidities, and continue to make more emergency department visits even after diagnosis. The mismatch isn't a failure of individual clinicians. It's a structural problem: a treatment framework built on limited sex-specific evidence, deployed in the population it was least designed to serve.

For more on POTS treatment options generally, see our guide to Natural Remedies for POTS (& When They're Not Enough).

Why a Neurological Approach Matters More for Women

Here's the key reframe: the heart isn't the problem. It's responding correctly to faulty signals from the autonomic nervous system—the part of the brain and body that regulates heart rate, blood pressure, breathing, and circulation. When that system misfires, the cardiovascular symptoms follow. Treating the heart rate directly is managing the output of a broken system, not the break itself. And for women, whose autonomic dysfunction is hormonally modulated and shifts across the entire reproductive life cycle, the gap between symptom management and system repair is wider than it is for men.

Women's greater incidence of orthostatic intolerance is primarily attributed to differences in autonomic function—specifically how the parasympathetic nervous system withdraws during upright posture and how the sympathetic system overcompensates. The norepinephrine signaling that is central to this process behaves differently in women than in men, particularly across hormonal life stages.

The three systems most relevant to women's POTS align directly with a neurological treatment approach:

1. Autonomic regulation: The brainstem centers governing heart rate and blood pressure are the same centers disrupted by hormonal fluctuations during puberty, the monthly cycle, pregnancy, postpartum, and perimenopause. Strengthening the baseline resilience of these centers reduces the destabilizing impact of every hormonal shift, so the system holds up better even during the phases where hormones are working against it.
2. Vestibular calibration: The saccule—a structure in the inner ear that detects vertical position changes—is part of the vestibular-autonomic connection that worsens specifically during low-estrogen phases. Retraining this connection addresses one of the most consistent and cyclically recurring drivers of orthostatic symptoms in women.
3. Breathing mechanics: Women are more prone to hypocapnia (low CO₂) due to thoracic breathing patterns, and this tendency intensifies during high-progesterone phases when progesterone's effect on respiratory drive increases ventilation rate. Low CO₂ reduces cerebral blood flow and worsens autonomic instability. Retraining breathing is not just a peripheral lifestyle change, but a core intervention.

Think of it this way: standard POTS treatment adjusts to a room that's always too hot. A neurological approach recalibrates the thermostat.

Treating the Neurological Root Causes of POTS at Cognitive FX

Cognitive FX's approach to POTS emerged from clinical observation, not a research laboratory. While treating patients with post-concussion syndrome who also had POTS, the team consistently observed autonomic recovery through neurological rehabilitation. Those methods were formalized into a dedicated POTS program—grounded in real patient outcomes, not theory.

The program targets the three root systems driving orthostatic dysfunction: autonomic regulation, vestibular calibration, and breathing mechanics. It does not treat the heart rate directly. It treats the system generating the problem.

Our 5-day program includes:

• Comprehensive Evaluation: A full assessment of your autonomic function, including an fMRI brain scan to build a personalized treatment plan for the remaining four days.

• Neuro-Cardio Training: A proprietary interval-based method that retrains the sympathetic and parasympathetic branches of the autonomic nervous system to work in coordination—recalibrating the "gas" and "brake" so neither overreacts.
• Vestibular recalibration: Targeted retraining of the saccule and vestibular-autonomic connection to reduce the overreaction to standing.
• Breathing mechanics training: Retrains diaphragmatic breathing and CO₂/O₂ balance, addressing the hypocapnia common in POTS patients.
• Cranial nerve activation: Uses specific smell and taste inputs to influence brainstem centers regulating heart rate and breathing.
• CO₂-based therapies: CarboHaler inhalation and CO₂ recovery suit to improve oxygen delivery and tissue perfusion.
• Planned recovery blocks: Built into each day to protect tolerance and avoid symptom flare.

Patients leave with a personalized home program—a repeatable, tested framework for managing symptoms independently. For women, this means having a concrete daily protocol for the phases of their cycle when autonomic compensation is weakest, rather than generic lifestyle changes that don't account for hormonal fluctuation.

Note: For the vast majority of our POTS patients, fMRI brain scan results reveal neural inflammation similar to what we see in our patients with brain injuries, Long COVID, or other neurological infections. For more on the neurological connection between POTS and other injuries/infections, see Why Concussion Can Lead to Blood Pressure Changes and POTS and Yes, Long COVID Can Cause POTS.

For guidance on finding the right care, see Choosing the Right POTS Clinic: What to Look For and Why.

Program details: 5 days, 4–6 hours per day, $4,500 (includes evaluation, all treatment sessions, and follow-up consultations). Located in Provo, Utah. Most patients travel from across the US and internationally.

Who Is a Good Fit

Cognitive FX's POTS program is most appropriate for:

• Women whose symptoms cycle predictably with their period or worsen at specific hormonal life stages
• Women who developed or significantly worsened POTS postpartum
• Women in perimenopause experiencing new or worsening autonomic symptoms
• Women with long COVID or brain injury alongside POTS
• Women who have tried standard cardiovascular management—medication, salt intake, compression garments, reconditioning—without adequate or lasting relief

To find out whether the Cognitive FX POTS program is right for you, complete our intake form at cognitivefxusa.typeform.com/pots-intake or call us at 385-446-4158. A member of our care team will be in touch to discuss your history and answer your questions.

Relevant and Cited Research

• Fedorowski A. Postural orthostatic tachycardia syndrome: clinical presentation, aetiology and management. J Intern Med. 2019;285(4):352–366. https://pubmed.ncbi.nlm.nih.gov/30372565/
• Fitzgibbon-Collins LK et al. Women, orthostatic tolerance, and POTS: a narrative review. Auton Neurosci. 2025. https://www.sciencedirect.com/science/article/pii/S1566070225000463
• Bourne KM et al. Symptom Presentation and Access to Medical Care in Patients With Postural Orthostatic Tachycardia Syndrome: Role of Sex. Mayo Clin Proc Innov Qual Outcomes. 2021;5(6):1203–1213. https://pmc.ncbi.nlm.nih.gov/articles/PMC8712580/
• Seeley MC et al. Biological sex-dependent differences in postural orthostatic tachycardia syndrome. Eur J Cardiovasc Nurs. 2025;24(5):762–771. https://academic.oup.com/eurjcn/article/24/5/762/8095354
• Stickford ASL et al. Menstrual cycle phase does not affect sympathetic neural activity in women with postural orthostatic tachycardia syndrome. J Physiol. 2015;593(9):2131–2143. https://pmc.ncbi.nlm.nih.gov/articles/PMC4422567/
• Fu Q et al. Menstrual Cycle Affects Renal-Adrenal and Hemodynamic Responses During Prolonged Standing in the Postural Orthostatic Tachycardia Syndrome. Hypertension. 2010;56(1):82–90. https://pmc.ncbi.nlm.nih.gov/articles/PMC2894615/
• Peggs KJ et al. Gynecologic disorders and menstrual cycle lightheadedness in postural tachycardia syndrome. Int J Gynaecol Obstet. 2012;118(3):242–246. https://www.sciencedirect.com/science/article/abs/pii/S0020729212002615
• Morgan K, Smith A, Blitshteyn S. POTS and Pregnancy: A Review of Literature and Recommendations for Evaluation and Treatment. Int J Womens Health. 2022;14:1831–1847. https://pmc.ncbi.nlm.nih.gov/articles/PMC9795856/
• Blitshteyn S et al. Postural Orthostatic Tachycardia Syndrome, Menopause and Hormone Replacement Therapy: Clinical Decisions in Times of Uncertainty. J Clin Med. 2026;15(4):1477. https://www.mdpi.com/2077-0383/15/4/1477
• Gibbons CH et al. Pubertal Hormonal Changes and the Autonomic Nervous System: Potential Role in Pediatric Orthostatic Intolerance. Front Neurosci. 2019;13:1197. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6861527/
• Miller AJ et al. The face of postural tachycardia syndrome — insights from a large cross-sectional online community-based survey. J Intern Med. 2020;287(2):147–157. https://pmc.ncbi.nlm.nih.gov/articles/PMC6790699/
• Wu J et al. The influence of sex on the treatment of postural orthostatic tachycardia syndrome. Medicine. 2023;102(28):e33951. https://journals.lww.com/md-journal/fulltext/2023/07140/the_influence_of_sex_on_the_treatment_of_postural.47.aspx
• Rosselló X et al. Beta-blockers after myocardial infarction: effects according to sex in the REBOOT trial. Eur Heart J. 2025. https://academic.oup.com/eurheartj/advance-article/doi/10.1093/eurheartj/ehaf673/8243876
• Fu Q et al. Exercise Training Versus Propranolol in the Treatment of the Postural Orthostatic Tachycardia Syndrome. Hypertension. 2011;58(2):167–175. https://www.ahajournals.org/doi/10.1161/hypertensionaha.111.172262
• Kwok CS et al. The evidence for treatments for postural orthostatic tachycardia syndrome: a systematic review of randomized trials. Trends Cardiovasc Med. 2025. https://www.sciencedirect.com/science/article/abs/pii/S1050173825000933
• Blitshteyn S et al. Sexual Dysfunction in Postural Orthostatic Tachycardia Syndrome (POTS): A Cross-Sectional, Case-Control Study. J Clin Med. 2024. https://pmc.ncbi.nlm.nih.gov/articles/PMC11050785/
• Bryarly M et al. Postural Orthostatic Tachycardia Syndrome: JACC Focus Seminar. J Am Coll Cardiol. 2019;73(10):1207–1228. https://www.sciencedirect.com/science/article/pii/S0735109719302190
• Mendelson O et al. Menstrual Cycle Variability in Symptoms of Postural Orthostatic Tachycardia Syndrome. Heart Lung Circ. 2022. https://www.heartlungcirc.org/article/S1443-9506(22)00628-X/fulltext
• Dysautonomia International. Diagnostic Delay in POTS. https://www.dysautonomiainternational.org/page.php?ID=184